Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences Inc. settled for $202 million over illegal kickbacks for HIV drug prescriptions, following Attorney General ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...